Atrioventricular septal defect prevention: Difference between revisions
Jump to navigation
Jump to search
(/* Recommendations for Endocarditis Prophylaxis (DO NOT EDIT){{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the management of adults with congenital heart dise...) |
m (Bot: Adding CME Category::Cardiology) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 13: | Line 13: | ||
|- | |- | ||
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Prophylaxis]] against [[IE]] is not recommended for nondental procedures (such as [[esophagogastroduodenoscopy]] or [[colonoscopy]]) in the absence of active [[infection]].''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Prophylaxis]] against [[IE]] is not recommended for nondental procedures (such as [[esophagogastroduodenoscopy]] or [[colonoscopy]]) in the absence of active [[infection]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
| Line 22: | Line 22: | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Antibiotic]] [[prophylaxis]] before dental procedures that involve manipulation of [[gingival]] tissue or the periapical region of teeth or perforation of the oral mucosa is reasonable in patients with [[CHD]] with the highest risk for adverse outcome from [[IE]], including those with the following indications:<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Antibiotic]] [[prophylaxis]] before dental procedures that involve manipulation of [[gingival]] tissue or the periapical region of teeth or perforation of the oral mucosa is reasonable in patients with [[CHD]] with the highest risk for adverse outcome from [[IE]], including those with the following indications:<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.''' [[Prosthetic cardiac valves]] or prosthetic material used for cardiac valve repair. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.''' [[Prosthetic cardiac valves]] or prosthetic material used for cardiac valve repair. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.''' Previous [[IE]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.''' Previous [[IE]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''c.''' Unrepaired and palliated cyanotic [[CHD]], including surgically constructed palliative [[shunts]] and conduits.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''c.''' Unrepaired and palliated cyanotic [[CHD]], including surgically constructed palliative [[shunts]] and conduits. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''d.''' Completely repaired CHD with prosthetic materials, whether placed by surgery or by [[catheter]] intervention, during the first 6 months after the procedure.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''d.''' Completely repaired [[CHD]] with prosthetic materials, whether placed by surgery or by [[catheter]] intervention, during the first 6 months after the procedure. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''e.''' Repaired CHD with residual defects at the site or adjacent to the site of a [[prosthetic]] patch or prosthetic device that inhibit endothelialization. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''e.''' Repaired [[CHD]] with residual defects at the site or adjacent to the site of a [[prosthetic]] patch or prosthetic device that inhibit endothelialization. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' It is reasonable to consider [[antibiotic]] [[prophylaxis]] against IE before [[vaginal]] [[delivery]] at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' It is reasonable to consider [[antibiotic]] [[prophylaxis]] against IE before [[vaginal]] [[delivery]] at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with the following indications:<nowiki>"</nowiki> | ||
the following indications:<nowiki>"</nowiki> | |||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.''' [[Prosthetic cardiac valves]] or prosthetic material used for cardiac valve repair. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.''' [[Prosthetic cardiac valves]] or prosthetic material used for cardiac valve repair. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.''' Unrepaired and palliated cyanotic CHD, including surgically constructed palliative [[shunts]] and conduits. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.''' Unrepaired and palliated cyanotic CHD, including surgically constructed palliative [[shunts]] and conduits. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
| Line 47: | Line 50: | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 04:16, 15 March 2016
|
Atrioventricular septal defect Microchapters |
|
Differentiating Atrioventricular septal defect from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Atrioventricular septal defect prevention On the Web |
|
American Roentgen Ray Society Images of Atrioventricular septal defect prevention |
|
Risk calculators and risk factors for Atrioventricular septal defect prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Prevention
2008 ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT)[1]
Recommendations for Endocarditis Prophylaxis (DO NOT EDIT)[1]
| Class III |
| "1. Prophylaxis against IE is not recommended for nondental procedures (such as esophagogastroduodenoscopy or colonoscopy) in the absence of active infection. (Level of Evidence: C)" |
| Class IIa |
| "1. Antibiotic prophylaxis before dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa is reasonable in patients with CHD with the highest risk for adverse outcome from IE, including those with the following indications:" |
| "a. Prosthetic cardiac valves or prosthetic material used for cardiac valve repair. (Level of Evidence: B)" |
| "b. Previous IE. (Level of Evidence: B)" |
| "c. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: B)" |
| "d. Completely repaired CHD with prosthetic materials, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure. (Level of Evidence: B)" |
| "e. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device that inhibit endothelialization. (Level of Evidence: B)" |
| "2. It is reasonable to consider antibiotic prophylaxis against IE before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with the following indications:" |
| "a. Prosthetic cardiac valves or prosthetic material used for cardiac valve repair. (Level of Evidence: C)" |
| "b. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.